Theragnostics Pipeline

Theragnostics proprietary clinical lead, THG-001 (THP-PSMA), is being developed with our Galli® technology to provide valuable diagnostic information on the status of patients with prostate cancer. A Phase I clinical trial of THG-001 was completed at the Peter MacCallum Cancer Centre in Melbourne during 2016, results of which will be published in a peer-reviewed journal. A Phase II trial is due to commence in mid-2017.

Theragnostics Pipeline
Representative images from the Phase I study of THG-001
(THP-PSMA)